Article thumbnail
Location of Repository

Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing

By Elio Coletta, Salvatore Coppolino, Febronia Federico and Francesco Fulia
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2909955
Provided by: PubMed Central

Suggested articles

Citations

  1. (2002). A cohort of children hospitalised with acute RSV bronchiolitis: impact on later respiratory disease. Pediatr Respir Rev
  2. (1989). Childhood asthma following hospitalization with acute viral bronchiolitis in infancy. Pediatr Pulmunol
  3. (2010). Cite this article as: Coletta et al., Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing Italian Journal of Pediatrics
  4. (2004). GL: Palivizumab: A review of use and prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs
  5. (2002). Groothuis JR: Respiratory syncytial virus prophylaxis-the story so far. Respir Med
  6. (1998). Group: Palivizumab, a humanized respiratory syncytial virus infection in high-risk infants. Pediatrics
  7. Immunoprophylaxis for respiratory syncytial virus.
  8. (2003). Respiratory syncytial virus.
  9. (2009). Sbragia U: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants.
  10. (2008). The cost and safety of multidose use of palivizumab vials. Clinical Pediatrics
  11. Using Visual Basic 6.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.